Afuresertib
Targeted therapy of multiple myeloma and various solid tumors
- CAS No.
- 1047644-62-1
- Indication Class
- Oncology / Hematology
- Patent Expiry
- To be assessed
- Therapeutic Area
- Oncology / Hematology
- Target / Mechanism
- AKT2·AKT3·AKT1
- Labeled Purity
- 99%+
- Registration Readiness
- GMP/DMF
- Commercialization Tier
- API (Commercialized)
- Linked Intermediates
- Confirm per inquiry
Key Intermediates for This API
Order: listed intermediates that accept enquiries first; fragments shared across several APIs rank higherNo intermediate entries are on file for this API yet. You can still enquire by CAS number — we will route it to the supply side for manual sourcing.
Listing Logic · Why It's Worth Listing
An oral pan-AKT inhibitor explored in both hematologic and solid tumors, a common targeted candidate within diagnosis-to-treatment integrated pathways.
Oncology / Hematology · Marketed; available for immediate sourcing
GMP/DMF-ready; supports regulatory filing and audit in target markets
Intermediates confirmed per inquiry
Data File Pack
Product Description
Afuresertib is an oral AKT kinase inhibitor that inhibits tumor cell growth by blocking the PI3K-AKT signaling pathway. It is primarily used in targeted therapy research for multiple myeloma and various solid tumors.
Supply source: Unibest · Afuresertib, sourced, vetted and delivered by Unibest. Therapeutic area, indication and listing rationale are qualitative summaries based on public drug knowledge for business reference; actual registration availability and quality specifications are subject to DMF/GMP documentation and the technical agreement confirmed at order.